
Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-Linked Severe Combined Immune Deficiency (XSCID) results in the Development of a Normal and Sustained Immune System: Interim Results of an ongoing Phase I/II Clinical Study

Journal: ASGCT

Publication Year: 0

Authors: Ewelina Mamcarz

PubMed link:

Funding Grants: Lentiviral Gene Therapy for Infants with X-linked Severe Combined Immunodeficiency using Autologous Bone Marrow Stem Cells and Busulfan Conditioning

Public Summary:

Scientific Abstract:

Source URL: <https://www.cirm.ca.gov/about-cirm/publications/lentiviral-gene-therapy-low-dose-busulfan-infants-x-linked-severe-combined>